Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PepsiCo

PepsiCo, Cardinal Health, and Baxter were among the large companies that declared dividend increases this week.

PepsiCo, Cardinal Health, and 3 Other Companies That Raised Their Dividends

Cardinal Health projected making capital expenditures in this fiscal year of between $400 million and $450 million; these investments will be primarily for information technology and infrastructure. On the IT side, Cardinal has invested in an advanced visibility solution.

Cardinal Health Invests In An Advanced Visibility Solution

Cardinal Health, Inc. (CAH) CEO Mike Kaufmann on Q3 2021 Results - Earnings Call Transcript

Cardinal Health (NYSE: CAH) reported the third-quarter FY21 adjusted EPS of $1.53, which missed the consensus estimate of $1.55. The earnings dropped 6% Y/Y, reflecting a higher non-GAAP effective tax rate.

Cardinal Health Stock Tumbles After Q3 Earnings Fall Short Of Expectations; Narrowed FY21 Adjusted EPS Guidance

Cardinal (CAH) delivered earnings and revenue surprises of -3.16% and -1.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Q3 Earnings and Revenues Lag Estimates

Cardinal Health's (CAH) fiscal third-quarter results reflect weakness in Pharmaceutical segment.

Cardinal Health (CAH) Q3 Earnings & Revenues Miss Estimates

Cardinal Health Inc. shares slid 8.8% in premarket trade Thursday, after the drug distributor posted weaker-than-expected earnings for its fiscal third quarter and lowered the top end of its guidance. The company said net income fell to $119 million, or 40 cents a share, in the quarter to March 31, down from $350 million, or $1.19 a share, in the year-earlier period.

Cardinal Health shares slide 8.8% premarket after earnings fall short of esimates

DUBLIN, Ohio, May 6, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third-quarter fiscal year 2021 revenue of $39.3 billion, in-line with the third quarter of last year. Third-quarter GAAP operating earnings decreased 16% to $473 million, primarily due to the write-down of the net assets held for sale from the planned divestiture of the Cordis business.

Cardinal Health reports third-quarter results for fiscal year 2021

Chubb

Clorox

Costco

Chevron

Johnson & Johnson

Kinder Morgan

Leggett & Platt

Lockheed Martin

Medtronic

Northrop Grumman

Procter & Gamble

Travelers

Dividend stocks continue to amaze. If the goal is to produce a passive income stream that will one day cover our expenses, making sure that income stream grows is critical.

6 Dividend Increases Expected In May 2021

On Thursday, May 06, Cardinal Health (NYSE:CAH) will release its latest earnings report. Here is Benzinga's outlook for the company.

Earnings Preview: Cardinal Health

DUBLIN, Ohio, April 27, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today launches Outcomes™, a digital ecosystem connecting pharmacists, payers and pharmaceutical companies to mitigate the challenges of medication non-adherence. Outcomes delivers digital health solutions for personalized medication therapy management, digital patient engagement, and telepharmacy, via its Connect™ platform, so these three customer groups can improve patient adherence to medication, drive better health outcomes for patients, and lower the cost of care.

Cardinal Health launches Outcomes™

Emerson Electric

Healthcare Services Group

As my goals have evolved, some companies in my portfolio no longer align with them. Regularly reviewing these positions and looking for alternatives is needed. HCSG, EMR, and CAH are three such companies. The low dividend growth is impacting the overall income growth in the portfolio.

Sell Or Hold - What To Do With These 3 Misfits

This podcast is brought to you by Ryder, the only fully integrated logistics & transportation provider in the industry. Ryder's solutions cover the entire supply chain including warehousing, transportation logistics, e-commerce fulfillment, & last mile.

Cardinal Health takes steps to increase visibility — Medically Necessary

The contract should help Cardinal Health (CAH) provide critical pandemic support in partnership with the U.S. government.

Cardinal Health (CAH), HHS Partner to Offer Pandemic Support

Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Cardinal (CAH) Could Beat Earnings Estimates Again

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.

Here's Why You Should Hold on to Cardinal Health (CAH) Stock

DUBLIN, Ohio, April 13, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the storage and distribution of 80,000 pallets of personal protective equipment (PPE) to support the Strategic National Stockpile (SNS), part of the Office of the Assistant Secretary for Preparedness and Response within HHS. "Cardinal Health is uniquely positioned to get critical products to healthcare providers and first responders as effectively, safely, and swiftly as possible in response to the COVID-19 pandemic," said Steve Mason, CEO Medical Segment.

Cardinal Health awarded Strategic National Stockpile contract for PPE storage and distribution

Con Ed

Coca-Cola

AT&T

Unilever

Vanguard High Dividend Yield ETF

Verizon

My dividend stock portfolio was burnt by dividend cuts in 2020 and lost over $800+ in forward dividend income. Therefore, I was ready to get back to basics and acquire more shares in the best quality dividend stocks out there. In total, my dividend stock purchases of VYM totaled $1,485.08, acquiring 15 total shares. This added $45 in forward dividend income.

Dividend Stock Purchase: Lanny's March 2021 Summary

Cardinal Health Inc. makes an attractive 11-15% annual free cash flow yield. The company offers high investor safety with a strong balance sheet, leading industry position, and Dividend Aristocrat status.

Cardinal Health: Exciting Opportunity In A Boring Industry

Cardinal Health (CAH) Specialty Solutions' newly launched Navista TS will help community oncologists to improve patient care and become successful in value-based care while reducing costs.

Cardinal Health (CAH) Unveils Navista TS to Boost Patient Care

DUBLIN, Ohio, April 7, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) Specialty Solutions today launched Cardinal Health™ Navista™ Tech Solutions (TS), an advanced suite of technology solutions to help community oncologists improve outcomes and costs associated with patient treatment as they transition to value-based care.  "Community-based oncology practices are facing unprecedented pressure as they pivot to adapt to value-based reimbursement models," said Heidi Hunter, President of Cardinal Health Specialty Solutions.

Cardinal Health Launches Navista™ TS to Help Oncology Practices Improve Patient Care, Lower Costs and Drive Success in Value-Based Care

Sysco

Union Pacific

You can't stop it, but you can give yourself a chance of keeping up with inflation.

Worried About Inflation? These 3 Stocks Can Help

DUBLIN, Ohio, March 30, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2021 on May 6 prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Cardinal Health to Webcast Discussion of Third-Quarter Results for Fiscal Year 2021 on May 6

Cardinal Health may be recovering from its opioid crisis setback in investor demand and valuation. Under normal operating circumstances, Wall Street would be valuing the stock at a price north of $100 currently.

Cardinal Health: Where Rising Price Meets A Bargain Valuation

Amgen

Bayer AG

CVS Health

Gilead Sciences

General Mills

Henkel AG & Co KGaA

Novo Nordisk

Reckitt Benckiser Group PLC

Walgreens

In the following article, I present 10 recession-proof stocks that are undervalued right now. Including companies from the healthcare sector like Gilead Sciences, Amgen, Novo Nordisk, Walgreens Boots Alliance, CVS Health, Cardinal Health and Bayer.

News for Cardinal Health Stock (CAH)